SHS sells leading enzyme engineering company c-LEcta GmbH to Kerry Group
- c-LEcta was able to translate technology leadership into tremendous commercial growth during the holding period of SHS
- Leipzig-based c-LEcta’s clients include international corporations in the pharmaceutical, chemical and food industries.
- With the acquisition, Kerry Group intends to further expand the internationalization of the company in the field of enzymes
Tübingen / 15.02.2022
The Tübingen-based growth investor SHS announces the sale of its stake in the technology leader in enzyme engineering, c-LEcta GmbH. The Irish Kerry Group, a leading global taste and nutrition partner for food, beverage and pharmaceutical markets, acquires the Leipzig-based company.
Today, c-LEcta is a leading innovator and supplier of biotech products for regulated markets such as food and pharmaceuticals. With over one hundred employees and world-class technologies for novel and cost-efficient industrial manufacturing processes, c-LEcta is one of the fastest growing companies in the market. Together with the strategic buyer, c-LEcta aims to further expand its range of bio-actives for food and pharmaceutical markets. SHS has invested in c-LEcta as a lead investor and has successfully driven the development of its products to market maturity and the international expansion of the company.
“SHS has been instrumental in supporting us with capital and strategic input on our journey to become a leading enzyme product provider. With the new partner Kerry Group, we want to take another growth step in our company’s history and are looking forward to the cooperation,” says c-LEcta CEO Marc Struhalla.
“We are pleased to have contributed to the tremendous growth of the company. Today, c-LEcta is an internationally important supplier for the pharmaceutical, chemical and food industries. We look back with pleasure on the journey we have taken together and wish the entire team continued success on their chosen path of growth,” comments SHS Managing Partner Uwe Steinbacher.
SHS has invested in c-LEcta from the third generation of SHS funds accompanied by a SHS co-investment fund refinanced by KfW.
About SHS Gesellschaft für Beteiligungsmanagement mbH:
“Building European Healthcare Champions” is the guiding principle of the Tübingen-based sector investor SHS. With this in mind, the investor specialising in healthcare investments finances and develops its portfolio companies. Since its foundation in 1993, the focus of its investments has been on expansion financing, shareholder changes and succession situations. In doing so, SHS takes both minority and majority stakes. Investors in SHS funds include pension funds, funds of funds, family offices, entrepreneurs, strategic investors and the SHS management team. The equity investment of the AIFM-registered company is up to EUR 20 million. Volumes exceeding this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ethical aspects. The investment company is committed to the principle of Socially Responsible Investing (SRI) and is a member of UN PRI, an investor initiative launched by the UN-Environment Programme. Its members contractually agree to comply with ecological and social guidelines in their investments. Companies financed by SHS so far include, for example, Phenox GmbH from Bochum, which specializes in stroke treatments, the drug delivery expert Develco Pharma AG, which is based in Switzerland and Germany, and the Swiss company evitria AG, a global market leader in the production of customized antibodies, which SHS recently sold very successfully. SHS is currently investing from its fifth fund, which was launched in 2018.
Further information at: http://www.shs-capital.eu
Would you like regular updates on SHS? Subscribe to our newsletter
and follow us on LinkedIn
About c-LEcta
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either as in-house development or in close cooperation with the industry. c-LEcta innovation capability delivers cost-efficient and sustainable production processes, creating growth opportunities across existing and new markets.
Press contact:
Sarah Stelzer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstraße 12
72072 Tübingen
sas@shs-capital.eu